Platform Programs
Diseases driven by specific bacterial genes (e.g., AMR, IBD)
Key Facts
About Eligo Bioscience
Eligo Bioscience is a private, preclinical-stage biotech based in Paris, developing a first-in-class platform for precision microbiome engineering. Its core GEM (Gene Editing of the Microbiome) platform enables the in vivo delivery of therapeutic DNA payloads to target bacteria, allowing for sequence-specific killing (SSAM), gene editing (GEM), or functional addition (FAME). The company, founded by CRISPR pioneers, is backed by notable investors and is advancing a pipeline focused on diseases causally linked to specific bacterial genes, as recently validated by a landmark 2024 publication in Nature.
View full company profileAbout United Immunity
A Japanese biotech developing DC-SIGN-targeting nanoparticle platforms for myeloid cell-specific drug delivery in oncology and immunology.
View full company profile